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-Aminobutyric acid aminotransferase (GABA-AT) is a
pyridoxal 5-phosphate-dependent enzyme responsible
for the degradation of the inhibitory neurotransmitter
GABA. GABA-AT is a validated target for antiepilepsy
drugs because its selective inhibition raises GABA con-
centrations in brain. The antiepilepsy drug, -vinyl-GABA
(vigabatrin) has been investigated in the past by various
biochemical methods and resulted in several proposals
for its mechanisms of inactivation. In this study we solved
and compared the crystal structures of pig liver GABA-AT
in its native form (to 2.3-Å resolution) and in complex with
vigabatrin as well as with the close analogue -ethynyl-
GABA (to 2.3 and 2.8 Å, respectively). Both inactivators
form a covalent ternary adduct with the active site Lys-
329 and the pyridoxal 5-phosphate (PLP) cofactor. The
crystal structures provide direct support for specific inac-
tivation mechanisms proposed earlier on the basis of radio-
labeling experiments. The reactivity of GABA-AT crystals
with the two GABA analogues was also investigated by
polarized absorption microspectrophotometry. The spec-
tral data are discussed in relation to the proposed mecha-
nism. Intriguingly, all three structures revealed a [2Fe-2S]
cluster of yet unknown function at the center of the dimeric
molecule in the vicinity of the PLP cofactors.
Two important neurotransmitters involved in the regulation
of brain neuronal activity are -aminobutyric acid (GABA),1
one of the most widely distributed inhibitory neurotransmit-
ters, and L-glutamic acid, an excitatory neurotransmitter (1).
The concentration of GABA is regulated by two pyridoxal 5-
phosphate (PLP)-dependent enzymes, L-glutamic acid decar-
boxylase, which catalyzes the conversion of L-glutamate to
GABA, and GABA aminotransferase (GABA-AT, EC 2.6.1.19),
which degrades GABA to succinic semialdehyde (2). GABA-AT
is a homodimer with each subunit containing an active-site
PLP covalently bound to Lys-329 via a Schiff base. The primary
sequence of GABA-AT has been deduced from the cDNA of pig
brain (3) and from peptide fragments of the pig liver enzyme
(4). Together with the structurally well characterized enzymes
ornithine aminotransferase (OAT) and dialkylglycine decar-
boxylase (DGD), GABA-AT belongs to the subfamily II of the
-family of PLP-dependent enzymes (5). In 1999, the x-ray
crystal structure of pig liver GABA-AT was reported at 3.0-Å
resolution (6), which elucidated the active-site geometry and
allowed conclusions to be drawn with respect to its specificity.
The mechanism for GABA-AT is well known (7). GABA is
transaminated to succinic semialdehyde, thereby converting
the pyridoxal 5-phosphate (PLP) cofactor to its pyridoxamine
5-phosphate (PMP) form. In the reverse half-reaction the en-
zyme is regenerated by conversion of -ketoglutarate to
glutamate.
When the concentration of GABA diminishes below a thresh-
old level in the brain, convulsions result (8), raising the brain
GABA levels terminates the seizure (9). The incidence of sei-
zure activity is very prevalent in the world. In fact, when
epilepsy is defined broadly as any disease characterized by
recurring convulsive seizures, then almost 1% of the entire
world population can be classified as having epilepsy (10).
Consequently, anticonvulsant agents have been sought for cen-
turies. Not until diphenylhydantoin (Dilantin) was introduced
onto the drug market over 65 years ago was any particular
anticonvulsant drug widely used (11). However, this drug is not
generally applicable. In fact, about one-quarter of epileptic
patients worldwide (about 12 million people) do not respond to
any marketed anticonvulsant drug. Therefore, the need for new
anticonvulsant drugs is great (10).
A reduction in the concentrations of GABA has been impli-
cated not only in the symptoms associated with epilepsy (12,
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13) but also with several other neurological diseases such as
Huntington’s chorea (14), Parkinson’s disease (15), Alzheimer’s
disease (16), and tardive dyskinesia (17). Administration of
GABA peripherally is not effective, because GABA, under nor-
mal conditions, cannot cross the blood-brain barrier; however,
several other approaches have been taken to increase the brain
concentrations of GABA. One approach is the use of a com-
pound that crosses the blood-brain barrier and then selectively
inhibits or inactivates GABA-AT, thereby causing a buildup of
GABA. Numerous competitive inhibitors of GABA-AT, partic-
ularly compounds having a backbone structure similar to
GABA (18–23), and a variety of mechanism-based inactivators
(24) of GABA-AT (25) show anticonvulsant activity. The earli-
est analog reported was 4-amino-5-hexynoic acid (1, -ethynyl
GABA, GEG), which did not become a clinical candidate (25).
The corresponding alkene, 4-amino-5-hexenoic acid (2, -vinyl
GABA, vigabatrin) (26), was the most effective of these mech-
anism-based inactivators as an anticonvulsant agent.
Vigabatrin (2), which has high potency (27), has been shown
to be an effective treatment for epilepsies that are resistant to
other anticonvulsant drugs (28) and currently is used in over 60
countries worldwide (but not in the U. S., where it is presently
at the pre-registration status for treatment of infantile
spasms). However, about 0.5 g of this drug has to be taken daily
to be efficacious. As with all psychotropic drugs, there are a
variety of side effects, most severe in this case is a visual field
defect (29), which restricts the monotherapy of vigabatrin to
refractory epilepsy. The drug is sold as a racemic mixture, and
it is not known how many of the side effects arise from the
administration of the inactive enantiomer (R-isomer). Other
mechanism-based inactivators of GABA-AT, such as gabacu-
line (30, 31) and ethanolamine-O-sulfate (32), are generally
toxic, nonspecific, and/or cross the blood-brain barrier poorly.
Recently, it was found that vigabatrin possesses another
remarkable activity: it prevents addiction to various abusive
substances in rats and baboons (33). The mechanism was de-
termined to be the same as that for epilepsy, namely increasing
the GABA concentration in the brain by inactivating GABA-
AT. Increased GABA levels antagonize the extracellular do-
pamine levels responsible for drug addiction. New inhibitors
that are in particular more potent and lipophilic, that is so they
can more easily cross the blood-brain barrier, are needed.
Two mechanisms were proposed for inactivation of GABA-AT
by GEG (34); these are shown in Schemes 1 and 2. For inacti-
vation by vigabatrin, three different potential mechanisms
(shown in Schemes 3 and 4) were suggested, based on spectro-
scopic and radiolabeling evidence (35), chemical intuition (26,
36), and extensive radiochemical experiments (37). The contro-
versy regarding the inactivation mechanisms and structures of
the covalent adducts could be settled with crystal structures of
these inactivators bound to GABA-AT.
Here, we have been able to use crystallography and polarized
absorption microspectrophotometry to differentiate the inacti-
vation mechanisms and adduct structures for the two mecha-
nism-based inactivators of GABA-AT, GEG (1), and vigabatrin
(2). Moreover, we report the presence of a [2Fe-2S] cluster at
the center of the dimer, observed in the complex structures as
well as in the native enzyme at 2.3-Å resolution.
MATERIALS AND METHODS
Crystallography—Pig liver GABA-AT was purified as described pre-
viously (35). Crystals of native enzyme were grown at room tempera-
ture in sitting drops by vapor diffusion and microseeding. The protein
solution (10–14 mg/ml in 40 mM sodium acetate, pH 5.4) was mixed in
a 1:1 ratio with precipitant solution containing 16–18% polyethylene
glycol4000, 0–10% glycerol, and 50 mM sodium cacodylate, pH 6.0, and
1 mM dithiothreitol.
The GEG-inactivated GABA-AT crystals were obtained by overnight
soaking of native crystals in a solution containing 10 mM GEG. Viga-
batrin-inactivated GABA-AT crystals were obtained by pre-treatment
of native GABA-AT with 10 mM vigabatrin for 1 h prior to crystalliza-
tion. Each data set was obtained from a single flash-cooled crystal using
either 10% ethylene glycol or PanjellyTM (Jena Bioscience) as cryopro-
tectants. Only a few cycles of crystal annealing were performed to
improve crystal mosaicity. Data were collected on MAR image plates,
processed with MOSFLM, and scaled with SCALA from the CCP4 suite
(38). The models were refined with REFMAC5, including TLS refine-
ment (39). Strong non-crystallographic symmetry restraints were im-
posed on the positional and thermal parameters of the four monomers
in the asymmetric unit. In the initial rounds of refinement, the cofactor
and Lys-329 were set as dummy values. This was followed by cyclic
averaging using DM (40) to obtain the best unbiased map for interpre-
tation of the adducts. After model building, refinement of the final
model was performed without torsional angle restraints on the linkages
between Lys-329, cofactor, and the inhibitor moiety. Planarity was
imposed on the atoms of the pyridine ring, the carboxylate group, and,
in case of the GEG complex, on the atoms belonging to the planar
system of the CAC double bond.
Chemical Analysis of Iron and Sulfur Content—The amount of iron
bound to GABA-AT was determined colorimetrically, by using the iron
chelator ferrozine (41). GABA-AT (5–10 M, 460 l) was mixed with
ultrapure concentrated HCl (100 l) and was incubated at 80 °C for 20
min with periodic vortexing. Following centrifugation at 15,000 rpm for
5 min to pellet the denatured protein, the supernatant (510 l) was
mixed with 10 mM ferrozine (20 l) and 75 mM ascorbic acid (20 l). To
allow ferrozine chelation, the mixture was neutralized with saturated
ammonium acetate and incubated for 20 min at room temperature. The
absorbance at 562 nm of the newly formed magenta Fe(ligand)3
2 spe-
cies was determined, and the iron concentration was calculated using
the extinction coefficient for ferrozine,   27,900 M1 cm1 (41). Acid-
labile inorganic sulfide was determined by the method of King and
Morris (42).
Crystal Microspectrometry—Crystals of GABA-AT were stored at
15 °C in a stabilizing solution containing 22% (w/v) polyethylene glycol
4000, 50 mM sodium citrate, and 1 mM dithiothreitol at pH 5.6. The
GABA-AT complexes were produced by soaking single crystals in the
stabilizing solution containing 100 mM GEG or 10 mM vigabatrin, re-
spectively. Crystals were loaded in a quartz flow cell that was mounted
on the thermostated stage of a Zeiss MPM03 microspectrophotometer,
equipped with a 10 UV-visible Ultrafluar objective. Single crystal
absorption spectra were collected in the range 300–700 nm with the
electric vector of the linearly polarized light parallel and perpendicular
to the extinction directions, as previously described (43, 44). The iso-
tropic crystal spectrum Ai of GABA-AT was calculated according to Ai 
1/3(Ax  Ay  Az), where Ax, Ay, and Az are the spectra recorded along
the three perpendicular extinction directions (45).
Coordinates—The coordinates for native GABA-AT, and its complex
structures with GEG and vigabatrin, have been deposited in the Rut-
gers Protein Data Bank (accession codes 1ohv, 1ohy, and 1ohw,
respectively).
RESULTS
Overall Structure—The quality of the native GABA-AT data
(2.3 Å) has been considerably improved since the previous
study (6) due to better crystal order, use of flash-cooled crys-
tals, and data acquisition at a synchrotron radiation source.
Crystallographic details are given in Table I. The new struc-
ture confirms the previous model. The asymmetric unit con-
tains two physiological dimers (AB and CD) with C2 symmetry.
The two dimers superimpose with an r.m.s.d. of 0.23 Å, and the
four subunits show pairwise r.m.s.d. values between 0.18 and
0.30 Å. This indicates that, within the limits of error, there is
no structural asymmetry between the four different copies in
the crystallographic asymmetric unit. Also, considering the
STRUCTURES 1 AND 2
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good quality of the overall crystallographic parameters (Table
I), it appears unlikely that asymmetric dimers have been in-
corporated stochastically into the crystal lattice. Refinement of
global temperature factors (TLS refinement), however, re-
vealed that AB is the more mobile dimer within the crystal
lattice. After TLS refinement, the remaining (intrinsic) B-fac-
tors of the subunits were virtually identical. This allowed the
imposition of strong NCS constraints not only on the positional
parameters but also on the individual B-factors.
The Native Cofactor: Structure and Absorption Spectrum—
All four copies of the PLP cofactor in the asymmetric unit form
a Schiff base linkage with Lys-329 (Fig. 1) and exhibit similar
B-factors (between 15 and 20 Å2) after TLS refinement. With a
torsional angle  (for torsion angle definition and atom nomen-
clature see Fig. 4C) of 23°  3° the Schiff’s base nitrogen is
roughly in the plane of the pyridine ring and forms a short
H-bond with the pyridine oxygen (O3) indicative of a proto-
nated aldimine. The torsional angle around the formal C4N
double bond is 140°  2°. Thus, the conformation appears to be
rather strained.
Single crystal polarized absorption spectra of GABA-AT, re-
corded along three perpendicular directions (Fig. 2), exhibit an
intense band centered at 412 nm. This band is usually attrib-
uted to the ketoenamine tautomer of the protonated internal
aldimine (i.e. with the proton on the aldimine nitrogen). How-
ever, there is a second band centered between 333 and 338 nm.
A band at a similar position has been found in several PLP-de-
pendent enzymes (43, 46) and has been attributed to the eno-
limine tautomer of the internal aldimine (with the proton on
the pyridine oxygen), a species stabilized by a more hydropho-
bic environment (47). Noteworthy, the position of the minor
band changes with the polarization direction, which suggests
that this band does not originate from a single electronic tran-
sition, but results from overlapping bands. The reconstructed
isotropic spectrum of the crystal (Fig. 2, inset) is similar to the
spectrum of the enzyme in solution (35) with respect to both the
peak positions and relative intensities, indicating that crystal-
lization did not perturb the coenzyme environment or the tau-
tomeric equilibrium.
[2Fe-2S] Cluster—Unexpectedly, a [2Fe-2S] cluster was
identified on the molecular 2-fold symmetry axis at the center
of the dimer in all structures investigated (Fig. 3, A and B).
Previously, it was not possible to resolve this feature because of
poor resolution (3 Å) (6). Fig. 3B shows that cysteines 135 and
138 at the N-terminal end of helix 5 together with their sym-
metry related mates chelate the cluster. Each of the iron atoms
SCHEME 2
SCHEME 1
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is coordinated tetrahedrally by two cysteines of one subunit
and the two free sulfur atoms, which lie on the molecular 2-fold
axis and cross-link to the symmetry related second iron atom.
The Fe–S distances are 2.2–2.3 Å. The B-factors of the cluster
atoms and the cysteines match well (differences  4 Å2).
A 2.3-Å anomalous difference density map computed with
data collected at a wavelength of 0.98 Å (vigabatrin complex,
cluster atoms omitted for phasing) shows peaks with a height
5  (Fig. 3C). The peaks are even more pronounced (8 ) in a
map computed with data collected to the same resolution with
CuK radiation at a home source (data not shown). This is to be
expected for iron with its absorption edge at 1.7 Å and rules out
the presence of zinc or other lighter elements.
Chemical analysis of the iron and acid-labile sulfide content
of freshly purified GABA-AT corroborated the crystallographic
interpretation. In four independent experiments, a content of
0.9–1.2 iron atoms per enzyme subunit was determined. The
sulfide content was 0.8 and 0.9 (two experiments). In proteins,
[2Fe-2S] clusters typically show absorption in the visible range
of the spectrum with peaks around 330 nm, 420–460 nm, and
a broad shoulder centered at 550 nm (48). Thus, in GABA-AT,
any iron-sulfur cluster absorption will be largely concealed by
the cofactor. A shoulder around 550–600 nm, however, is
clearly visible in the crystal absorption spectrum (Fig. 2) as in
solution (49). This is absent in the homologous OAT (49) that
contains no FeS cluster.
SCHEME 4
SCHEME 3
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GABA-AT in Complex with GEG—The electron density map
of GABA-AT obtained upon soaking of crystals with GEG,
clearly shows a covalent modification at the active site (Fig.
4A). The internal aldimine linkage between Lys-329 and PLP of
the native enzyme (Fig. 1) has been broken. Instead, a covalent
ternary adduct is formed among the cofactor, the inhibitor, and
the lysine residue. Fig. 4C demonstrates that the pyridine ring
is only slightly tilted (about 5°) with respect to its native
orientation. In accord with this, Phe-189 has moved by 0.6 Å.
As anticipated earlier (6), the carboxylate group of the inhibitor
forms a salt bridge with the guanidinium group of Arg-192,
which is found pushed outwards by 0.7 Å when compared with
the native enzyme.
The density shows that the distance between the two nitro-
gens (NZ and N) of the PLP-lysine linkage is spanned by three
and not four bonds, thus indicating that the reaction has pro-
ceeded according to the mechanism depicted in Scheme 2 and
not by the mechanism in Scheme 1. In fact, the map was best
modeled with tautomer 10 of Scheme 2 (Fig. 4A), yielding a flat
residual difference map. Missing density for the branching C
atom in the unbiased map is probably the result of its modest
resolution (2.8 Å) or some heterogeneity, i.e. the presence of
some of the other tautomers shown in Scheme 2 (see “Discus-
sion”). The distance of the branching methyl group to the Ile-72
side chain is rather short ranging from 3.0 to 3.3 Å in the
individual active sites. The plane of the pyridine ring is roughly
perpendicular to the plane defined by the CAC double bond.
The (unconstrained) C4–C4–N–CA torsional angle around the
formal C4N double bond is 155°. Both nitrogen atoms of the
linkage (N and NZ) are in H-bonding distance to the pyridine O3.
The reaction of GEG with GABA-AT crystals was monitored
by measuring polarized absorption spectra as a function of
crystal-soaking time (Fig. 5A). A slow decrease of the band at
412 nm was observed with a concomitant increase of the band
at 337 nm with an isosbestic point at about 370 nm, indicating
the formation of an inhibitorenzyme complex. The complex
was found to be very stable (Fig. 5A, inset), as observed in
solution,2 suggesting an irreversible covalent linkage between
GEG and the enzyme.
GABA-AT in Complex with Vigabatrin—Soaking of
GABA-AT crystals in vigabatrin solution did not yield inter-
pretable electron density for the adduct (see also below). Co-
crystallization, however, yielded the structure depicted in Fig.
4B. Again, a ternary adduct among Lys-329, the cofactor, and
the inhibitor has formed, but this time the electron density
indicates the presence of four bonds joining N with NZ. There-
fore, it can be ruled out that intermediates of the alternative
Michael addition pathway and the enamine pathway (Scheme
4) are present in significant amounts. Instead, a model of the
2 D. De Biase, unpublished results.
TABLE I
Data collection and refinement statistics
The GABA-AT crystals are of space-group P21 and contain two dimers in the asymmetric unit.
Data set Native Vigabatrin complex GEG complex
Sample Native GABA-AT GABA-AT co-crystallized with
10 mM vigabatrin
GABA-AT soaked in 10 mM
GEG for 24 h
X-ray source; (Å) ESRF, Grenoble; 0.984 Elettra, Trieste; 0.984 Rotating anode; 1.542
Unit cell: a, b, c (Å) 68.6, 225.0, 70.3 69.7, 226.7, 71.4 69.0, 225.9, 70.3
 (°) 108.4 108.8 108.5
Resolution range (Å) 30.0–2.3 30.0–2.3 30.0–2.8
Number of reflections 80,297 88,767 42,802
Rsym (%)
a 8.5 7.3 9.8
	I
/(I) 5.9 6.7 6.6
Completeness (%) 90.0 96.1 85.7
Multiplicity 2.0 2.2 2.5
Rfactor (%)
b 18.8 19.4 19.8
Rfree (%)
c 22.1 22.4 22.9
Number of protein atoms 29,216 29,216 29,216
Number of cofactor atoms 15 24 24
Number of FeS atoms 8 8 8
Number of water molecules 641 739 337
Mean overall B-factor (Å2)d 24.0 (18.1) 26.3 (11.9) 25.9 (9.2)
r.m.s.d. bond lengths (Å)e 0.009 0.010 0.012
r.m.s.d. bond angles (°)e 1.1 1.2 1.4
a Rsym hkli(I(hkl)  	I(hkl)
)/hkli 	I(hkl)
.
b Rfactor is the conventional R factor.
c Rfree is the R factor calculated with 5% of the data that were not used for refinement.
d In parentheses, residual overall B-factor after TLS refinement.
e r.m.s.d. from ideal stereochemistry.
FIG. 1. Stereographic projection of
the active site of GABA-AT. The final
model is shown together with the 2Fo  Fc
map (contour level, 1.2 ). An acetate mol-
ecule is found close to Arg-192, i.e. at a
position where the carboxylate moiety of
the natural substrate GABA is expected
to bind (6).
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external aldimine 15 that can occur after Michael addition at
the terminal carbon of the vinyl group by the active site lysine
(Scheme 3) fits the electron density best and yields a flat
difference map. The adduct model is well accommodated in the
active site of the enzyme with the NZ amino group forming an
H-bond with the main-chain carbonyl of residue 72 and the
aldimine NH, which lies in the plane of the pyridine ring
forming an H-bond with O3. The adduct appears to be in a
rather relaxed conformation with an (unconstrained) torsion
angle around the C4–N aldimine linkage of 169°.
To monitor the kinetics of the reaction in the crystal, polar-
ized absorption spectra were acquired of GABA-AT crystals
that were soaked in a vigabatrin solution (Fig. 5B). A gradual
decrease in the band at 412 nm with a concomitant increase of
the band at 337 nm was observed with an isosbestic point at
365 nm. The spectral changes were complete in about 3 h (Fig.
5B, inset). At longer times, a decrease of both band intensities
was apparent, whereas their intensity ratio remained constant,
probably indicating release of a modified cofactor from the
crystal. The reaction appears to be irreversible, because the
removal of the reagent after 9 h of incubation did not lead to a
reversal of the spectral changes. When the reaction of the
enzyme with vigabatrin is carried out in the presence of 10 mM
-ketoglutarate (to convert any PMP form back to the compe-
tent PLP form), the same spectral changes were observed,
although at a slower rate (data not shown).
An attempt was made to follow these changes structurally by
incubating GABA-AT crystals for a defined length of time be-
fore flash cooling and data acquisition. Several data sets were
collected after incubation with vigabatrin for 3–24 h (data not
shown). In all cases it was evident that a reaction had occurred
as judged by the absence of a covalent aldimine linkage be-
tween C4 of the cofactor and NZ of Lys-329 due to a motion of
the tip of the lysine side-chain and a slight though significant
tilt of the cofactor ring. Coarse modeling gave a C4 to NZ
distance of 2.5–3 Å, somewhat smaller than the corresponding
distance (4.0 Å) in the vigabatrin co-crystallization complex
(Fig. 4B). The remainder of the density did not allow unambig-
uous interpretation. In all cases, density was found close to
Arg-192, probably representing the carboxylate group of the
inhibitor. Addition of -ketoglutarate did not alter the results
significantly.
DISCUSSION
The [2Fe-2S] Cluster—An unexpected finding of the current
study is the presence of an iron-sulfur cluster at the center of
the GABA-AT dimer that is clearly resolved (Fig. 3). The pres-
ence of metals in mammalian GABA-AT, although suspected,
was never reported in previous biochemical studies. The com-
plexity of the visible absorption spectrum of GABA-AT was
initially assigned to anomalous binding of PLP (50). Iron-sulfur
clusters are well known in enzymology for their important
functions in electron transfer processes, but they also are now
known to catalyze dehydration reactions, to stabilize protein
structure, to regulate metabolic pathways, to act as biological
sensors of iron, molecular oxygen, and superoxide, nitric oxide
and are involved in the formation of protein-bound radicals
(51). In GABA-AT the [2Fe-2S] cluster cross-links the subunits
of the physiological dimer. It appears unlikely that this is its
only role, because structurally homologous proteins such as
human OAT (52) and bacterial DGD (53) exhibit the same
subunit organization, but lack a cross-linker at the dimer in-
terface. The same is true for all other aminotransferases of
known structure. To the best of our knowledge, there are no
other iron-sulfur cluster-containing enzymes that have a clus-
ter exclusively for subunit cross-linking. Iron-sulfur clusters
can be destroyed by oxidation (for a review see Ref. 54) and can
exert in this way a redox state sensing function. Because the
iron-sulfur cluster of GABA-AT is observed without resorting to
anaerobic conditions, its stability does not seem to be exquis-
itely sensitive to oxidation.
Interestingly, cysteines 135 and 138, which chelate the clus-
ter, are conserved in the GABA-AT sequences of higher orga-
nisms, including Drosophila, but are not present in bacteria
and yeast, with the exception of the basidiomycete Ustilago
maydis. It is conceivable that during biogenesis the iron-sulfur
cluster is needed for the proper association of GABA-AT sub-
units to form the functional dimer. This then may happen only
in the strongly reducing environment of the mitochondria and
would ensure that the enzyme becomes active only at its
destination.
Alternatively, the redox state of the cluster may regulate
indirectly the activity of the enzyme as suggested by the rela-
tively short distance between the cluster and the two active
sites (Fig. 3B). Most interestingly, a direct influence of nitric
oxide (which is known to modulate the redox state of iron-
sulfur clusters) on GABA-AT activity in rat brains has recently
been reported (55). The presence of an iron-sulfur cluster in
PLP enzymes has been recently observed in biotin synthase
(56) and lysine 2,3-aminomutase (57). In these cases, the iron-
sulfur cluster is directly involved in catalysis, which is not the
case for GABA-AT. Clearly, in vitro studies have to be per-
formed to characterize and to clarify the role of the [2Fe-2S]
cluster in mammalian GABA-AT.
Native Structure and Cofactor Spectrum—In the native en-
zyme, the PLP cofactor is bound to Lys-329 via a Schiff base
linkage, and there is no evidence for a structural asymmetry
between the active sites of the dimer as previously reported
(50). The short distance between the aldimine N and the pyri-
dine O3 indicates that the cofactor is protonated. The aldimine
linkage appears strained, because the conjugated systems of
the cofactor ring and the linkage are not coplanar (with the
aldimine N having a distance of 0.6 Å to the cofactor plane, Fig.
1). This strained conformation is observed in several PLP en-
zymes, e.g. in tryptophan synthase (58) (PDB code 1QOP, struc-
FIG. 2. Polarized absorption spectra of native GABA-AT crys-
tals. Spectra were recorded with the polarization direction along the
three mutually perpendicular extinction directions of the monoclinic
GABA-AT crystals and are shown with distinct line-types. Inset, calcu-
lated isotropic spectrum.
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ture determined to 1.4-Å resolution) and should be important
to catalysis by raising the ground state energy of the aldimine
(59).
It is known that the GABA-AT cofactor does not titrate
between pH 5.5 and 9 (60), i.e. the aldimine N has a pKa above
9. In aspartate aminotransferase (AAT), which titrates in the
neutral pH range, the deprotonated aldimine double bond is
rotated out of the ring plane ( about 80° (61)). A similar
rotation is prevented by the presence of Val-300 (which corre-
sponds to Ala-224 in AAT), and this may explain the high pKa
value of the cofactor. The absence of an equivalent of AAT
Tyr-225, which can stabilize the uncompensated single charge
FIG. 3. The [2Fe-2S] cluster at the center of the GABA-AT dimer. A, structure of the GABA-AT dimer. The view is approximately along the
molecular 2-fold symmetry axis. The C traces of the two subunits are shown in black and red. Helix 5 and its symmetry mate are highlighted by
thick gray traces. The [2Fe-2S] cluster on the molecular 2-fold symmetry axis together with the liganding cysteines and the two symmetry related
PLP cofactors are shown in full view. B, close-up view of A. The C traces have been omitted for clarity. Symmetry-related residues are marked
with the symbol “#.” C, stereographic close-up view. The molecular 2-fold axis is approximately along the vertical direction. The native 2Fo  Fc
omit map (magenta; contour level 1.2 ) and the anomalous difference map (light blue; contour level 4.5 ) were computed with data to
2.3-Å resolution (data set of the vigabatrin complex). The iron and sulfur atoms were not included for phasing.
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on the pyridine O3 in AAT, offers another possible explanation.
The visible absorption spectrum (Fig. 2) shows two peaks as
have also been observed for the PLP forms of AAT at low pH
(62) and of tryptophan synthase (43). These can tentatively be
assigned to the protonated aldimine in the ketoenamine
(max  412 nm) and enolimine (max  335 nm) form. Another
interpretation would be that the non-coplanarity of the PLP
ring and the aldimine linkage can cause the occurrence of two
electronic transitions for the ketoenamine form, as has been
demonstrated by Clark et al. (62). Their semiempirical calcu-
lations showed that the positions of the absorption bands vary
with the torsional angle  and can fall in a range that is
observed for GABA-AT (and other PLP enzymes). In the crystal
spectrum (Fig. 2), the polarization ratios differ for the two
bands, which is consistent with a different orientation of the
coenzyme in the ketoenamine and enolimine tautomers and/or
FIG. 4. A, stereographic projection of the active site of GABA-AT after chemical modification with GEG. The final model is shown together with
the cyclic averaged omit maps (contour level, 1.0 ). The ternary adduct has been modeled according to structure 10 of Scheme 2. B, stereographic
projection of the active site of GABA-AT after chemical modification with vigabatrin. The final model is shown together with the cyclic averaged
omit maps (contour level, 1.0 ). The ternary adduct has been modeled according to structure 15 of Scheme 3. C, comparison of adduct structures.
The models of the native PLP cofactor forming an aldimine linkage with Lys-329 (carbon atoms colored in cyan) of the ternary adduct in the
GABA-ATGEG complex (carbons in gray), and of the ternary adduct in the GABA-ATvigabatrin complex (carbons in magenta) are shown. For this
comparison the active-site protein residues have been superimposed. Side chains Phe-189 and Arg-192 are found slightly shifted upon formation
of the ternary complexes. The schematic drawing defines the torsional angle  and the nomenclature of the atoms.
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different directions of the dipole transition moments. The var-
iability of the position of the peak assigned to the enolimine
tautomer with polarization direction suggests that this band
does not originate from a single electronic transition. Whether
this results from a contribution of the iron-sulfur cluster has
yet to be investigated.
Inactivation by GEG—This study is part of a project to un-
ravel the structure and function of GABA-AT for the develop-
ment of inhibitory drugs to control GABA levels in the brain. A
first result in this direction has been published recently (63).
GEG (1), one of the first rationally designed mechanism-based
inactivators, was shown to be a potent inactivator of GABA-AT
(30, 64, 65). In vivo, GEG causes a long-lasting decrease in
mouse brain GABA-AT activity in a dose-dependent manner
when administered peripherally and has been shown to in-
crease synaptosomal GABA levels (66, 67).
Two inactivation mechanisms for GEG have been reported
(34). In Scheme 1, following Schiff base formation with the
active site PLP, -(CA)-proton removal and tautomerization
into the cofactor gives the ,-ethynyliminium complex (5), a
highly electrophilic species, which would undergo reaction at
the terminal carbon atom of the ethynyl group (36) with Lys-
329. Scheme 2 is similar to Scheme 1 except after -(CA)-proton
removal, tautomerization occurs with the ethynyl group to give
6, a conjugated allene, which can undergo reaction at the pe-
nultimate carbon with the active site lysine residue (34, 36, 64)
(at the time of publication it was not known that the nucleo-
phile is Lys-329, as shown in Schemes 1 and 2).
These two mechanisms, which differ in the point of attach-
ment of Lys-329 to the inactivator, have now been differenti-
ated by crystallography (Fig. 4A). Lys-329 was found to be
attached to the penultimate carbon, thereby supporting the
overall mechanism in Scheme 2. Attack of 6 by Lys-329 can
lead to four different tautomers (7-10). Following inactivation
of [7-3H]PLP-reconstituted GABA-AT by GEG and denatu-
ration, PLP was released, which is consistent only with 7, 9,
and 10 (34).
On steric grounds, as well as the [7-3H]PLP experiment
described above, structure 8 is highly unlikely, because it is not
possible to bring the C4 of the coenzyme into the plane defined
by the ketimine double bond. Modeling of the remaining tau-
tomers (7, 9, and 10) and subsequent refinement yielded com-
parable fits with the density. The well defined positions of the
PLP cofactor, the lysine side chain, and the inhibitor cofactor
(Fig. 4A) impose strong constraints on the geometry of the
linkage. For adducts 7 and 9, the distance between NZ and C4
is 2.1–2.4 Å (depending on the subunit), which is unreasonably
close. This distance is increased to 2.5–2.6 Å for adduct 10.
Although still rather strained, this tautomer clearly represents
the best fit of the structural data. Credence to this interpreta-
tion is given also by the close to planar torsional angle around
the aldimine double bond. The crystal structure, therefore,
clearly confirms the mechanism proposed based on radiolabel-
ing experiments (34). The crystal absorption spectrum of
GABA-AT after incubation with GEG (Fig. 5A) shows the two
bands of the native spectrum (Fig. 2), although with a change
in relative height. Thus, the spectrum is compatible with the
aldimine 10, with a shifted ketoenamine/enolimine equilibrium
compared with the native structure. The CACB double bond
probably does not contribute to the visible spectrum, because
its orientation is roughly perpendicular to the pyridine plane.
The presence of other ternary adducts of Scheme 2, however,
cannot be ruled out. The reaction proceeds more slowly than
that with vigabatrin (see below), leading to the formation of a
stable complex, as observed in solution. This is consistent with
the observed covalent link between the inhibitor, the PLP, and
the protein.
Inactivation by Vigabatrin—Three different inactivation
mechanisms for GABA-AT by vigabatrin (2) have been reported
(Schemes 3 and 4). One mechanism (Scheme 3) involves azal-
lylic isomerization followed by -proton removal as in the nor-
mal catalytic mechanism with substrate. Unlike GABA, viga-
batrin is converted into an electrophilic species (12), which
could undergo Michael addition at the terminal carbon of the
vinyl group by the active site Lys-329 to give 13. Adduct 13 can
easily be tautomerized to 14 or 15. An alternative Michael
addition pathway (Scheme 4) requires allylic isomerization
through the vinyl double bond to give 16, which also is a
Michael acceptor. This can be attacked by Lys-329 to give
attachment of the nucleophile at the penultimate carbon of the
former vinyl group to yield 17 and 18 (path a). Or, alterna-
tively, Lys-329 can attack the PLP imine carbon rather than
undergoing Michael addition, leading to enamine 19, which can
condense with the PLP imine to give adduct 20 (path b).
Lippert et al. (26) proposed the mechanism in Scheme 3 up to
intermediate 13. Metcalf (36) suggested two possibilities:
Scheme 3 up to intermediate 13 and the mechanism in Scheme
4 to give 17. On the basis of [14C]vigabatrin labeling experi-
ments and mass spectrometry on the radiolabeled peptide, De
Biase et al. (35) ruled out the enamine mechanism (Scheme 4,
path b), because no coenzyme was detected in the peptide-
inhibitor adduct. They suggested that their data were consist-
ent with the formation of either 14 or 17. Nanavati and Silver-
man (37) used [7-3H]PLP-reconstituted GABA-AT and
FIG. 5. Polarized absorption spectra of GABA-AT crystals in
the presence of GEG and vigabatrin. Spectra were recorded with
light linearly polarized along the crystal extinction direction with
higher absorption intensity. A, spectra measured in the absence (solid
lines) and presence of 100 mM GEG after 90 min (dashed lines) and 1200
min (dotted lines). B, spectra measured in the absence (solid lines) and
presence of 10 mM vigabatrin after 30 min (dashed lines) and 180 min
(dotted lines). The insets show the time course of the A337 nm/A412 nm
peak absorption ratio and the A337 nm peak absorption.
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[6-14C]vigabatrin and showed that denaturation of the inacti-
vated enzyme releases PMP and the enamine adduct from 20 in
a 75:25 ratio, thereby supporting the enamine mechanism as a
minor pathway and either 14 (Scheme 3) or 17 (Scheme 4), both
of which would release PMP upon denaturation, as the major
pathway. Further studies on the reactivity and reactions of the
major adduct (37) led to the conclusion that 14 was the actual
inactivation adduct.
The crystal structure of vigabatrin bound to GABA-AT (Fig.
4, B and C) elucidates the structure of the covalent adduct as
one in which Lys-329 is attached to the terminal carbon of the
vinyl group as proposed in Scheme 3, effectively ruling out the
mechanisms shown in Scheme 4. It is not possible to differen-
tiate between the ternary adducts 13-15 based on the electron
density (Fig. 4B) alone, and there may be even more than one
tautomer present in the crystal. The geometry appears most
relaxed for tautomer 15 with an (unconstrained) torsion angle
around the N–CA aldimine linkage of 169° and a  torsion
angle of 1° resulting in coplanarity of the aldimine linkage with
the pyridine ring and a favorable H-bond between the ionized
NH and O3. Structure 15 is not consistent with the biochem-
ical result that after denaturation PMP is formed; instead the
release of PLP would be predicted. Tautomerization from 15 to
14, however, would lead to the observed release of PMP under
the conditions of the denaturation, but it is not clear why that
tautomerization should occur.
The crystal spectrum of GABA-AT after treatment with vi-
gabatrin (Fig. 5B) is compatible with the presence of the less
conjugated system of ketimine 14, the aldimine 15 with a
shifted ketoenamine/enolimine equilibrium, the aldimine spe-
cies 12, or species 11. Because the cofactor is gradually re-
leased from the crystal (Fig. 5B, inset), one can conclude that
there is no covalent linkage between the cofactor and the pro-
tein, which is in disagreement with the crystal structure. Ap-
parently, the different ways the vigabatrin complex had to be
produced for structure determination (complex formation in
solution and subsequent crystallization) and for spectroscopic
analysis (crystal soaking) are relevant for resolving this issue.
We suggest that, in the soaked crystal, the reaction does not
progress efficiently beyond the formation of the external aldi-
mine (12), which would be the species that gets released with
time. The next step (Scheme 3) would require rotation of the
vinyl group toward the active site lysine, which may well be
hindered by a reduced conformational flexibility of the active
site due to crystal lattice constraints. For the reaction with
GEG, such a conformational change is not required, and the
reaction can proceed to form a stable ternary complex. Overall,
these findings point out that crystalline proteins might not
behave as in the soluble form, because small, but functionally
essential conformational changes may be prevented or the
equilibrium distribution of species may be perturbed, causing
unanticipated reactivity (44, 68).
Why is only the Michael addition adduct (14) observed in the
vigabatrin structure and not the enamine adduct (20)? Possi-
bly, the Michael addition complex is thermodynamically more
stable than the enamine adduct, which would thus have been
lost over the time needed for crystallization. As a result, a
partially occupied Michael complex would be left in the crystal.
Indeed, test refinement of the model with a partially occupied
adduct showed that the occupancy can be set as low as 75%
without getting unreasonable B-values. This is consistent with
the 75:25 ratio of Michael addition to enamine addition adducts
previously observed (37). Alternatively, a small fraction of ac-
tive sites containing the enamine adduct (20) would not con-
tribute significantly to the observed density (which is the av-
erage over all active sites).
In summary, we have obtained high resolution crystal struc-
tures of GABA-AT inactivated by GEG and vigabatrin. Each of
these structures has clarified the products of inactivation,
which then allowed for the elucidation of the major mecha-
nisms of inactivation. This approach does not require the tedi-
ous and time-consuming synthesis of radiolabeled compounds
and structure elucidation by peptide mapping. Although pep-
tide mapping and mass spectrometry are important tools to
identify sites of modification, they do not provide precise ad-
duct structure information of crystallography needed to aid in
the elucidation of reasonable inactivation mechanisms. How-
ever, as a note of caution, had the inactivation mechanism for
vigabatrin been based solely on the crystal structure, the minor
enamine inactivation pathway would have been overlooked.
The adduct structures described here will serve as a starting
point for the development of mechanism-based inactivators and
reversible inhibitors to target specifically GABA-AT. The
native structure has already led to the design of a vigaba-
trin analog that is converted exclusively by the enamine
mechanism (63).
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